EUVIMED · CrossrefJournal
The Lancet Rheumatology
ISSN 2665-9913 · Elsevier BV
Latest articles
Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study
Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Harmonising difficult-to-manage and complex-to-manage psoriatic arthritis: from divergent prevalence estimates to reproducible, mechanism-aware phenotypes
The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease
Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study
Redefining long-term success in systemic sclerosis
When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective
Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study
Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial
Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY
Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials
Addressing the urgent need for clinical trials in chronic non-bacterial osteomyelitis
Impact of the COVID-19 pandemic on autoimmune rheumatic disease diagnoses
Prediction of psoriatic arthritis risk: watch for symptoms
BMI as a modifier of Janus kinase inhibitor response in rheumatoid arthritis
The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice? – Authors' reply
Infection risk in adults with secondary HLH
Translating progress into patient benefit in dermatomyositis
Research in Brief
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study
Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study
The role of health literacy in clinical, treatment, and work-related outcomes in people with inflammatory arthritis in England: a cross-sectional study
The at-risk-to-early continuum of enteropathic spondyloarthritis
Interferon-α in Sjögren's disease: cause or consequence?
Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial
Health literacy and outcomes in people with inflammatory arthritis
The erosion of seronegative autoimmune diseases through the lens of autoantibodies
EUVIMED